| + |
Aflibercept | down-regulates activity 
chemical inhibition
|
VEGFB |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259387 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 22813448 |
Aflibercept, a fusion protein with binding domains from native VEGF receptors, binds VEGF-A, VEGF-B, and placental growth factors 1 and 2 with high affinity.This soluble decoy receptor is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which then is fused to the Fc region of human IgG-1.2 Aflibercept binds to all VEGF-A and VEGF-B isoforms, as well as the highly related placental growth factor. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
VEGFB | up-regulates 
|
Angiogenesis |
0.7 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-252276 |
|
|
|
|
| pmid |
sentence |
| 17326328 |
More than a dozen different proteins have been identified as angiogenic activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor (TNF)-α, platelet-derived endothelial growth factor, granulocyte colony-stimulating factor, placental growth factor, interleukin-8, hepatocyte growth factor, and epidermal growth factor |
|
| Publications: |
1 |
| + |
bevacizumab | down-regulates activity
binding
|
VEGFB |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259885 |
|
|
Homo sapiens |
Colorectal Cancer Cell |
| pmid |
sentence |
| 15961063 |
Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
VEGFB
- 
- 